<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665544</url>
  </required_header>
  <id_info>
    <org_study_id>CEEGOG EX-02</org_study_id>
    <nct_id>NCT04665544</nct_id>
  </id_info>
  <brief_title>Tracers for Endometrial Cancer Sentinel Node Labeling</brief_title>
  <acronym>TESLA-1</acronym>
  <official_title>Prospective Observational Study on Sentinel Node Biopsy Using Two Concurrent Labelling Techniques (Radioactive Tracer With/Without Blue Dye vs. Indocyanine Green-ICG) in Early-stage Endometrial Cancer Patients (TESLA-1).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Maribor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Maribor</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel lymph node (SLN) biopsy is currently used in the management of vulvar and breast&#xD;
      cancers as well as in malignant melanoma, and is being intensively studied in patients with&#xD;
      cervical and endometrial cancers. The role of lymphadenectomy in the surgical management of&#xD;
      early-stage endometrial cancer is still controversial. The main reason to perform a SLN&#xD;
      biopsy is to detect the lymph node that will be the first involved with metastatic disease in&#xD;
      the nodal basin. The SLN biopsy is performed after the SLN is located with the use of&#xD;
      different tracers in a concept called SLN mapping. Moreover, SLN evaluation has been reported&#xD;
      to improve the accuracy of lymph node staging due to SLN pathologic ultrastaging, which&#xD;
      includes multiple serial sectioning and immunohistochemical assessment. The aim of this&#xD;
      project is to conduct a multicentre, prospective, observational trial to compare two&#xD;
      different SLN labelling methods (radioactive tracer with/without blue dye vs. indocyanine&#xD;
      green-ICG) in the same patient and to evaluate the unilateral detection rate, sensitivity,&#xD;
      number of detected SLN, anatomical localisation of detected SLN and bilateral detection rate&#xD;
      of SLN. The main aim of the trial is the comparison of SLN mapping between two SLN labelling&#xD;
      methods in the same patient. The trial will answer a question whether a combination of&#xD;
      labelling methods in the same patient increase importantly the sensitivity of SLN biopsy.&#xD;
&#xD;
      The trial has a high potential to reach the calculated number of cases and thus bring in&#xD;
      evidence/data that will be essential for future management of SLN biopsies in endometrial&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLN unilateral detection rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of hemipelvises where the SLN was found/number of all hemipelvises for each tracer and combination of tracers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of SLN biopsy for pelvic lymph node staging. Anatomical localisation of detected SLN</measure>
    <time_frame>2 years</time_frame>
    <description>Number of true positive LN/(number of true positive LN+number of false negative LN) for each tracer and combination of tracers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of detected SLN.</measure>
    <time_frame>2 years</time_frame>
    <description>Average number of detected SLN (in the specimen, labelled with the tracer, there might be one or more LN; the number of removed LN is one of the quality indicator).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive meassure: Anatomical localisation of detected SLN</measure>
    <time_frame>2 years</time_frame>
    <description>Exact anatomical localisation of SLN (1-external iliac vessels, 2-internal iliac vessels, 3-obturator region, 4-paraaortic region, 5-presacral region).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral detection rate.</measure>
    <time_frame>2 years</time_frame>
    <description>The number of patients with bilateral SLN detection/the number of all patients for each tracer and combination of tracers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Early-stage endometrial cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Histologically proven endometrial cancer (any tumour type).&#xD;
Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.&#xD;
Performance status ECOG: 0-1.&#xD;
Age ≥18, ≤85.&#xD;
History of second primary cancer only if more than 5 years with no evidence of disease.&#xD;
Approved and signed informed consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.</intervention_name>
    <description>The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).&#xD;
The null hypothesis is that the detectionrate does not differ between the two techniques.</description>
    <arm_group_label>Early-stage endometrial cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven endometrial cancer (any tumour type).&#xD;
&#xD;
          -  Apparent early-stage endometrial cancer with intermediate or high risk prognostic&#xD;
             factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological&#xD;
             type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant&#xD;
             metastases on preoperative conventional imaging studies; minimum requirement for&#xD;
             clinical staging includes expert US or pelvic MRI for local staging and abdominal US&#xD;
             or abdominal CT scan or PET CT for distant staging.&#xD;
&#xD;
          -  Performance status ECOG: 0-1.&#xD;
&#xD;
          -  Age ≥18, ≤85.&#xD;
&#xD;
          -  History of second primary cancer only if more than 5 years with no evidence of&#xD;
             disease.&#xD;
&#xD;
          -  Approved and signed informed consent form to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Desire for fertility sparing&#xD;
&#xD;
          -  History of pelvic or abdominal radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Pakiž, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Maribor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maja Pakiž, MD, PhD</last_name>
    <phone>+38623212583</phone>
    <email>maja.pakiz@ukc-mb.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andraž Dovnik, MD, PhD</last_name>
    <phone>+38623212178</phone>
    <email>andraz.dovnik@ukc-mb.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Klat</last_name>
      <email>jaroslav.klat@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Aneta Neničkova</last_name>
      <email>aneta.nenickova@fno.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charles University-First Faculty of Medicine, University Hospital Bulovka, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Student</last_name>
      <email>vladimir.student@bulovka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Hana Urbankova</last_name>
      <email>hana.urbankova@bulovka.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology Center, Department of Obstetrics and Gynecology; First Faculty of Medicine, Charles University of Prague and General Hospital in Prague</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cibula, MD, PhD</last_name>
      <email>David.Cibula@vfn.cz</email>
    </contact>
    <contact_backup>
      <last_name>Renata Poncova</last_name>
      <email>renata.poncova@vfn.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>KNTB Zlin</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Havelka</last_name>
      <email>havelka@bnzlin.cz</email>
    </contact>
    <contact_backup>
      <last_name>Martina Hajdonova</last_name>
      <email>Martina.Hajdonova@bnzlin.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology, Gynecologic Oncology and Endocrinological Gynecology, Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Wydra</last_name>
      <email>dwydra@uck.gda.pl</email>
    </contact>
    <contact_backup>
      <last_name>Anna Abacjew-Chmyeko</last_name>
      <email>anabacjew@gumed.edu.pl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical centre Maribor, Department for Gynecologic and Breast Oncology</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Pakiž, PhD</last_name>
      <email>maja.pakiz@ukc-mb.si</email>
    </contact>
    <contact_backup>
      <last_name>Andrej Cokan, MD</last_name>
      <email>andrej.cokan@ukc-mb.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Maribor</investigator_affiliation>
    <investigator_full_name>Maja Pakiz</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

